Antag Therapeutics
Copenhagen, DK · Founded 2017 · 23 employees on LinkedIn · 3 known investors
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.
Founders & leadership
Antag Therapeutics was founded in 2017 by Jens Juul Holst and Mette Rosenkilde.
JJ
Jens Juul HolstFounder
MR
Mette RosenkildeFounder
Investors · 3
Frequently asked questions
- What does Antag Therapeutics do?
- Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.
- Who founded Antag Therapeutics?
- Antag Therapeutics was founded by Jens Juul Holst, Mette Rosenkilde in 2017.
- Who are Antag Therapeutics's investors?
- Antag Therapeutics's investors include Broadview Ventures, Novo Holdings, SR One Capital Management.
- Where is Antag Therapeutics headquartered?
- Antag Therapeutics is headquartered in Copenhagen, DK.